INMED PHARMACEUTICALS INC. Impairment Charge on Reclassified Assets
INMED PHARMACEUTICALS INC. (INM) reported Impairment Charge on Reclassified Assets of $1.20 million for the 12-month period ending 2022-06-30, per its 10-K filed 2023-09-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentChargeOnReclassifiedAssets · last filed 2023-09-29
- INMED PHARMACEUTICALS INC. impairment charge on reclassified assets for fiscal 2022 was $1.20M.
| Period end | Impairment Charge on Reclassified Assets 12 month | Impairment Charge on Reclassified Assets 12 month as first filed |
|---|---|---|
| 2022-06-30 | $1.20M 10-K · filed 2023-09-29 | $1.20 10-K · filed 2022-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |